Atlas Trials

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

Clinical trial NCT05014100 · UNKNOWN

Trial details

NCT number
NCT05014100
Sponsor
Puyang Oilfield General Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
B-cell Lymphoma
Start date
2021-09-01
Primary completion
2022-09-30
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.